AKBA
AKBA
NASDAQ · Biotechnology

Akebia Therapeutics Inc

$0.41
-0.01 (-2.80%)
As of Nov 7, 2:08 AM ET ·
Financial Highlights (FY 2026)
Revenue
261.85M
Net Income
-5,929,645
Gross Margin
82.9%
Profit Margin
-2.3%
Rev Growth
-6.9%
D/E Ratio
5.94
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 82.9% 82.9% 34.7% 34.7%
Operating Margin 9.9% 9.0% -4.5% -4.8%
Profit Margin -2.3% -2.2% -5.9% -6.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 261.85M 281.19M 65.59M 81.13M
Gross Profit 217.10M 233.14M 22.75M 28.15M
Operating Income 26.05M 25.18M -2,955,557 -3,890,676
Net Income -5,929,645 -5,730,971 -3,878,355 -4,942,326
Gross Margin 82.9% 82.9% 34.7% 34.7%
Operating Margin 9.9% 9.0% -4.5% -4.8%
Profit Margin -2.3% -2.2% -5.9% -6.1%
Rev Growth -6.9% -6.9% +11.6% -8.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 50.45M 50.45M 21.85M 26.69M
Total Equity 8.50M 8.50M 127.43M 136.15M
D/E Ratio 5.94 5.94 0.17 0.20
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 26.06M 26.58M -4,128,349 -4,627,733
Free Cash Flow — — -1,979,346 -2,914,255